Host targeted inhibitors of dengue virus and other viruses
US-9879003-B2 · Jan 30, 2018 · US
Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
US11608338B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11608338-B2 |
| Application number | US-202117204619-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 17, 2021 |
| Priority date | Apr 2, 2015 |
| Publication date | Mar 21, 2023 |
| Grant date | Mar 21, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound, which is one of the following compounds: 1-(3,5-Difluoropyridin-2-yl)-7-methoxy-3- methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3,5-Difluoropyridin-4-yl)-7-methoxy-3- methyl-8-(1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3,5-Difluoropyridin-2-yl)-7-methoxy-3- methyl-8-(1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3-Fluoropyridin-2-yl)-7-methoxy-3- methyl-8-(1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3-Fluoro-5-methylpyridin-4-yl)-7- methoxy-3-methyl-8-(1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3-Fluoropyridin-4-yl)-7-methoxy-3- methyl-8-(1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3,5-Difluoropyridin-2-yl)-8-(1,3-dimethyl- 1H-pyrazo1-4-yl)-7-methoxy-3-methyl-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3-Ethyl-5-fluoropyridin-4-yl)-7-methoxy-3- methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3-Fluoropyridin-2-yl)-7-methoxy-3- methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 8-(1,3-Dimethyl-1H-pyrazol-4-yl)-1- (3-fluoropyridin-2-yl)-7-methoxy-3-methyl-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3-Fluoro-5-methylpyridin-4-yl)-7- methoxy-3-methyl-8-(1-methyl-1H-pyrazol- 4-yl)-1,3-dihydroimidazo[4,5-c]quinolin-2- one 7-Methoxy-3-methyl-1-(3-methylpyridin-4- yl)-8-(1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3-Fluoro-5-methylpyridin-2-yl)-7- methoxy-3-methyl-8-(1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3,5-Difluoropyridin-4-yl)-7-methoxy-3- methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one 8-(1-Ethyl-1H-pyrazol-4-yl)-1- (3-fluoropyridin-2-yl)-7-methoxy-3-methyl- 1,3-dihydroimidazo[4,5-c]quinolin-2-one 1-(3-Ethyl-5-fluoropyridin-4-yl)-8-(1-ethyl- 1H-pyrazol-4-yl)-7-methoxy-3-methyl-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3,5-Difluoropyridin-4-yl)-8-(1-ethyl-1H- pyrazol-4-yl)-7-methoxy-3-methyl-1,3- dihydroimidazo[4,5-c]quinolin-2-one 1-(3-Fluoro-5-methylpyridin-2-yl)-7- methoxy-3-methyl-8-(1-methyl-1H-pyrazol- 4-yl)-1,3-dihydroimidazo[4,5-c]quinolin-2-one 7-Methoxy-1-(3-methoxypyridin-4-yl)-3- methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3- dihydroimidazo[4,5-c]quinolin-2-one
Assignees
Inventors
Classifications
specific for metastasis · CPC title
Antineoplastic agents · CPC title
not condensed and containing further heterocyclic rings · CPC title
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11608338B2 cover?
- Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
- Who is the assignee on this patent?
- Merck Patent Gmbh
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4375. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).